Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYMNASDAQ:IMUXNASDAQ:RZLTNASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$1.18-6.3%$1.25$2.35▼$11.55$35.11M-0.39486,688 shs3.60 million shsIMUXImmunic$0.70-1.5%$0.91$0.56▼$2.11$67.07M1.49964,359 shs747,317 shsRZLTRezolute$4.35+0.9%$3.98$2.22▼$6.19$372.01M1.04629,654 shs10.25 million shsSLGLSol-Gel Technologies$7.32-0.8%$7.35$3.34▼$16.50$20.42M1.133,085 shs6,948 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics0.00%-2.48%-3.28%-7.81%-83.40%IMUXImmunic0.00%-2.78%+6.21%-35.78%-36.94%RZLTRezolute0.00%+5.84%+6.36%+50.00%+1.16%SLGLSol-Gel Technologies0.00%-1.48%-0.27%+33.58%-17.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMUXImmunic2.74 of 5 stars3.61.00.00.03.22.50.6RZLTRezolute3.1056 of 5 stars3.61.00.00.04.24.20.0SLGLSol-Gel Technologies2.6619 of 5 stars3.53.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/AIMUXImmunic 3.25Buy$11.601,557.14% UpsideRZLTRezolute 3.14Buy$11.83172.03% UpsideSLGLSol-Gel Technologies 3.00Buy$40.00446.45% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, SLGL, RZLT, and ELYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AIMUXImmunicN/AN/AN/AN/A$0.20 per shareN/ARZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ASLGLSol-Gel Technologies$11.54M1.77N/AN/A$10.36 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AIMUXImmunic-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)Latest IMUX, SLGL, RZLT, and ELYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q1 2025SLGLSol-Gel TechnologiesN/A-$3.20N/A-$3.20N/A$1.03 million5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41IMUXImmunicN/A0.740.74RZLTRezoluteN/A8.438.43SLGLSol-Gel TechnologiesN/A5.125.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%IMUXImmunic51.82%RZLTRezolute82.97%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%IMUXImmunic4.60%RZLTRezolute18.39%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableIMUXImmunic7095.82 million91.41 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableIMUX, SLGL, RZLT, and ELYM HeadlinesRecent News About These CompaniesSLGL Sol-Gel Technologies Ltd. - Seeking AlphaJune 26, 2025 | seekingalpha.comSol-Gel Technologies LtdJune 21, 2025 | morningstar.comMSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comQSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comSol-Gel Announces Reverse Share SplitMay 1, 2025 | globenewswire.comSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comSol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.April 17, 2025 | finanznachrichten.deSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.April 17, 2025 | globenewswire.comGlobal Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth AnalysisApril 7, 2025 | globenewswire.comSol-Gel Technologies Approves Reverse Share Split and Compensation Policy RenewalApril 1, 2025 | tipranks.comSLGL Gears Up to Report Q4 Earnings: Here's What You Should KnowFebruary 25, 2025 | zacks.comIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?February 7, 2025 | finance.yahoo.comSol Gel Technologies Ltd (SLGL) Stock Trading RecapDecember 26, 2024 | bovnews.comBIs SolGel Technologies (SLGL) a Great Value Stock Right Now?December 25, 2024 | zacks.comSol-Gel Technologies Reports Strong Q3 2024 ResultsNovember 21, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, SLGL, RZLT, and ELYM Company DescriptionsEliem Therapeutics NASDAQ:ELYM$1.18 -0.08 (-6.35%) As of 06/27/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Immunic NASDAQ:IMUX$0.70 -0.01 (-1.46%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.68 -0.02 (-3.00%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Rezolute NASDAQ:RZLT$4.35 +0.04 (+0.93%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$4.38 +0.04 (+0.80%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Sol-Gel Technologies NASDAQ:SLGL$7.32 -0.06 (-0.88%) As of 06/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
